[HTML][HTML] Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
H Tilly, F Morschhauser, LH Sehn… - … England Journal of …, 2022 - Mass Medical Soc
Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of …
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of …
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R …
LH Sehn, B Berry, M Chhanabhai, C Fitzgerald, K Gill… - Blood, 2007 - ashpublications.org
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, with patients exhibiting a
wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP)has …
wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP)has …
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
LH Sehn, J Donaldson, M Chhanabhai… - Journal of clinical …, 2005 - ascopubs.org
Purpose For more than two decades, cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) has been the standard therapy for diffuse large B-cell lymphoma (DLBCL). …
prednisone (CHOP) has been the standard therapy for diffuse large B-cell lymphoma (DLBCL). …
[HTML][HTML] Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and …
Purpose Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC …
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC …
Diffuse large B-cell lymphoma
LH Sehn, G Salles - New England Journal of Medicine, 2021 - Mass Medical Soc
Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially, …
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially, …
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Z Zhou, LH Sehn, AW Rademaker… - Blood, The Journal …, 2014 - ashpublications.org
The International Prognostic Index (IPI) has been the basis for determining prognosis in
patients with aggressive non-Hodgkin lymphoma (NHL) for the past 20 years. Using raw clinical …
patients with aggressive non-Hodgkin lymphoma (NHL) for the past 20 years. Using raw clinical …
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
…, S Ben-Neriah, JM Connors, LH Sehn… - Blood, The Journal …, 2009 - ashpublications.org
Approximately 5% to 10% of diffuse large B-cell lymphomas (DLBCLs) harbor an MYC
oncogene rearrangement (MYC + ). The prognostic significance of MYC + DLBCL was …
oncogene rearrangement (MYC + ). The prognostic significance of MYC + DLBCL was …
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a …
…, HP Shulha, C Hother, JM Connors, LH Sehn… - The lancet …, 2015 - thelancet.com
Background Follicular lymphoma is a clinically and genetically heterogeneous disease, but
the prognostic value of somatic mutations has not been systematically assessed. We aimed …
the prognostic value of somatic mutations has not been systematically assessed. We aimed …
[HTML][HTML] Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
LH Sehn, AF Herrera, CR Flowers… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell
lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug …
lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug …
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
LH Sehn, RD Gascoyne - Blood, The Journal of the American …, 2015 - ashpublications.org
Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-…
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-…